Halim Alan, Kim Bryan, Kenyon Elizabeth, Moore Anna
Precision Health Program, Michigan State University, East Lansing, MI, USA.
Department of Radiology, College of Human Medicine, Michigan State University, East Lansing, MI, USA.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251339256. doi: 10.1177/15330338251339256. Epub 2025 May 21.
Despite advances in cancer detection and treatment, metastatic breast cancer continues to carry a poor prognosis due to the lack of diagnostic and therapeutic resources that are specific to the metastatic process. MicroRNA-10b (miR-10b) is a small, noncoding RNA that is the focus of many studies due to its unique role as a driver of metastasis. The pathways it is involved in and the properties it confers have been reviewed previously and, collectively, are suggestive of the potential of miR-10b as a clinical marker and as a therapeutic target specific to metastatic disease. With the goal of application of our understanding of miR-10b to the clinic, in this mini-review, we highlight the studies that support the utility of miR-10b for these translational purposes.
尽管在癌症检测和治疗方面取得了进展，但由于缺乏针对转移过程的诊断和治疗资源，转移性乳腺癌的预后仍然很差。微小RNA-10b（miR-10b）是一种小的非编码RNA，由于其作为转移驱动因子的独特作用而成为许多研究的焦点。它所涉及的途径及其赋予的特性此前已有综述，总体而言，提示了miR-10b作为临床标志物和转移性疾病特异性治疗靶点的潜力。为了将我们对miR-10b的理解应用于临床，在本综述中，我们重点介绍了支持miR-10b用于这些转化目的的研究。
